

Dated: February 29, 2008.

**Maryam I. Daneshvar,**

*Acting Reports Clearance Officer, Centers for Disease Control and Prevention.*

[FR Doc. E8-4650 Filed 3-7-08; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[60 Day-08-08AS]

#### Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 404-639-5960 and send comments to Maryam I. Daneshvar, CDC Acting Reports Clearance Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to [omb@cdc.gov](mailto:omb@cdc.gov).

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should

be received within 60 days of this notice.

#### Proposed Project

*Surveys of BioSense Trainings,—New—National Center for Public Health Informatics (NCPHI), Centers for Disease Control and Prevention (CDC).*

#### Background and Brief Description

Congress passed the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, which requires specific activities related to bioterrorism preparedness and response. This congressional mandate outlines the need for improving the overall public's health through electronic surveillance. The Department of Health and Human Services outlined strategies aimed at achieving this goal via the Public Health IT Initiative thereby creating the BioSense program.

BioSense is the national, human health surveillance system designed to improve the nation's capabilities for disease detection, monitoring, and real-time health situational awareness. This work is enhanced by providing public health real-time access to existing data from healthcare organizations, state syndromic surveillance systems, national laboratories, and others for just in time public health decision-making. BioSense data are analyzed through advanced statistical methods, and made accessible through the BioSense application. The application provides data, charts, graphs, and maps through a secure web-based interface which can be accessed by CDC and authorized state and local public health and hospital users.

In order to meet the congressional mandate, it is important that BioSense users understand the role of BioSense in daily surveillance as well as be able to use specific BioSense modalities to investigate or monitor any potential disease outbreaks and/or bioterrorist attacks. A series of training tools have been developed to educate BioSense

users about how best to utilize BioSense in these circumstances.

The training tools were developed based upon a 2007 needs assessment conducted among BioSense users. Training 1 is an online, self-paced training module designed for BioSense users at the beginner level who are not wholly familiar with BioSense or have not used the system on a regular basis. This module presents the background of BioSense and an overview of its general functions in a didactic training style. Training 2 is a virtual training filmed in Second Life. It is designed for intermediate to advanced level users who are aware of and have used the general BioSense functionalities for daily surveillance but want additional skills related to using BioSense during an emergency scenario. This scenario-based module is presented in an experiential training style.

Data collection will take place in the form of an online survey immediately following each training module and a link to an online survey emailed 3-months post training. This data collection will assess the goals of these trainings, which are to help registered BioSense users (1) establish knowledge and efficacy necessary to use BioSense to investigate and/or monitor a potential event or outbreak; (2) facilitate communication between BioSense administrators in public health and hospital settings; (3) access BioSense trainings that are engaging and easy to use; and (4) use BioSense to investigate and/or monitor a potential event or outbreak. The post-training and 3-month follow-up surveys have been pre-tested with less than 9 participants. Survey results will be used to identify the impact and applicability of these training modules for BioSense users.

There are no costs to survey respondents other than their time to participate.

#### ESTIMATED ANNUALIZED BURDEN HOURS

Form	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden (in hours)
Post-Training Survey .....	400	1	10/60	67
3-Month Follow Up Survey .....	320	1	5/60	27
Total .....				94

Dated: February 29, 2008.

**Maryam I. Daneshvar,**

*Acting Reports Clearance Officer, Centers for Disease Control and Prevention.*

[FR Doc. E8-4651 Filed 3-7-08; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Clinical Laboratory Improvement Advisory Committee: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92-463) of October 6, 1972, that the Clinical Laboratory Improvement Advisory Committee, Centers for Disease Control and Prevention, Department of Health and Human Services, has been renewed for a 2-year period through February 19, 2010.

For information, contact Thomas Hearn, PhD, Executive Secretary, Clinical Laboratory Improvement Advisory Committee, Centers for Disease Control and Prevention, Department of Health and Human Services, 1600 Clifton Road, NE., Mailstop C12, Atlanta, Georgia 30333, telephone 404/718-1048 or fax 404/639-3039.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: February 29, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-4719 Filed 3-7-08; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): "Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory Confirmed Medically Attended Outcomes", Funding Opportunity Announcement (FOA) IP08-001 and "Influenza Vaccine Efficacy in Tropical and Developing Countries", FOA IP08-002

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting.

*Time and Date:* 9 a.m.-5 p.m., April 30, 2008 (Closed).

*Place:* Centers for Disease Control and Prevention, Atlanta, GA.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

*Matters To Be Discussed:* The meeting will include the review, discussion, and evaluation of "Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory Confirmed Medically Attended Outcomes", Funding Opportunity Announcement (FOA) IP08-001 and "Influenza Vaccine Efficacy in Tropical and Developing Countries", FOA IP08-002."

*For Further Information Contact:* Christine J. Morrison, Ph.D., Scientific Review Administrator, CDC, 1600 Clifton Road, NE., Mailstop D72, Atlanta, GA 30333, Telephone: (404) 639-3098.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: February 29, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-4754 Filed 3-7-08; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Center for Injury Prevention and Control/ Initial Review Group, (NCIPC/IRG)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned review group:

#### *Times and Dates:*

1 p.m.-1:30 p.m., March 26, 2008 (Open)

1:30 p.m.-5 p.m., March 26, 2008 (Closed)

*Place:* Teleconference.

*Status:* Portions of the meetings will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5, U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Section 10(d) of Public Law 92-463.

*Purpose:* This group is charged with providing advice and guidance to the Secretary, Department of Health and Human Services, and the Director, CDC, concerning the scientific and technical merit of grant and cooperative agreement applications received from academic institutions and other public and private profit and nonprofit organizations, including State and local government agencies, to conduct specific injury research that focuses on prevention and control.

*Matters To Be Discussed:* The meeting will include the review, discussion, and evaluation of cooperative agreement applications submitted in response to Fiscal Year 2008 Requests for Applications related to the following individual research announcement: CE08-007, Assessing the Effects of Interpersonal Violence Prevention on Suicide.

Agenda items are subject to change as priorities dictate.

*For Further Information Contact:* J. Felix Rogers, Ph.D., M.P.H., Telephone (770) 488-4334, CDC, 4770 Buford Highway, NE., M/S F62, Atlanta, Georgia 30341-3724.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: February 29, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office Centers for Disease Control and Prevention.*

[FR Doc. E8-4643 Filed 3-7-08; 8:45 am]

BILLING CODE 4163-18-P